Dr. Géraldine Androdias reveals how immune checkpoint inhibitors affect multiple sclerosis, highlighting a low risk of relapse in MS patients undergoing cancer treatments. Dr. Bob Fox dives into the significance of neurofilament light chain as a biomarker for disease progression, stressing the need for more research. Dr. Ellen Iacobaeus discusses the unique clinical traits of late-onset MS, advocating for personalized therapy approaches. Additionally, insights on family planning for MS patients underscore the importance of supportive discussions between patients and healthcare providers.

Dr. Abbatemarco and Dr. Iacobaeus discuss the impact of late-onset MS, including poor prognosis risk factors, diagnostic delays, higher disability levels, less frequent treatment, and faster disease progression in patients with late-onset MS.

Dr. Ellen Iacobaeus discusses late-onset MS in Swedish patients, highlighting differences with adult-onset MS like higher disability levels and less inflammation. She explores challenges in therapy, prescribing patterns, and managing late-onset MS patients, emphasizing the need for tailored treatment and vigilant monitoring.